2-溴-5-嘧啶羧酸甲酯 | 1209459-66-4

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-溴-5-嘧啶羧酸甲酯
• 中文别名: 甲基2-溴嘧啶-5-羧酸乙酯
• 英文名称: Methyl 2-bromopyrimidine-5-carboxylate
• CAS: 1209459-66-4
• 化学式: C₆H₅BrN₂O₂
• mdl: MFCD14702815
• 分子量: 217.02
• InChiKey: ARONDYLNDUEGTF-UHFFFAOYSA-N

物化性质

• 沸点：
  327.4±34.0 °C(Predicted)
• 密度：
  1.669±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H318

文献信息

• Benzimidazole derivatives useful as CB-1 inverse agonists
  申请人：Janssen Pharmaceutica NV

  公开号：US10118900B2

  公开（公告）日：2018-11-06

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.

  本发明涉及苯并咪唑衍生物、含有苯并咪唑衍生物的药物组合物及其在治疗由 CB-1 受体介导的紊乱和病症中的用途；更具体地说，是在治疗对 CB-1 受体的反向激动有反应的紊乱和病症中的用途。更具体地说，本发明的化合物可用于治疗代谢紊乱。
• BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20170057929A1

  公开（公告）日：2017-03-02

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
• [EN] BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE UTILES À TITRE D'AGONISTES INVERSES DE CB-1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017035114A1

  公开（公告）日：2017-03-02

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.